Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

Assistance Publique - Hôpitaux de Paris1,250 enrolled

Overview

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

The collection of data from patients with CHC and cholangiocarcinomas who are cancers with poor prognosis is a major challenge to improve patients'care (diagnosis, prognosis); facilitate the search for new therapeutic targets and the follow-up of clinical studies; and develop personalized treatments.

Study Type

OBSERVATIONAL

Enrollment

1,250

Conditions

Cholangiocarcinoma Hepatocellular Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Inclusion Criteria : * Age ≥ 18 years olds * Medical care in Nephrology department since 2015 Cholangiocarcinoma: \- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease Hepatocellular carcinoma: * Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI * Hepatocellular histologically documented Exclusion Criteria: \- Lack of patient non-opposition

Locations (1)

Serviec hépatologie-Hôpital Saint Antoine

Paris, France

RECRUITING

Outcomes

Primary Outcomes

Overall survival

Hepatocellular carcinoma and Cholangiocarcinoma : Overall survival is defined as the survival 5 years after the inclusion.

Time frame: 5 years

Secondary Outcomes

Overall survival

Hepatocellular carcinoma :Overall survival is defined as the survival after 5 years of inclusion.

Time frame: 5 years

Disease free survival

Cholangiocarcinoma : 2 and 5 years after surgical resection

Time frame: 2 and 5 years

Progression time under chemotherapy

Cholangiocarcinoma : Time of progression under chemotherapy is defined by the delay between the start of chemotherapy and tumor progression (appearance of a new lesion or increase in size of more than 30%)

Time frame: Time of progression under chemotherapy up to 5 years

Central Contacts

Marie LEQUOY, MD

CONTACT

+330149283154 marie.lequoy@aphp.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.